Cingulate Inc.
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is …
Biotechnology
US, Kansas City [HQ]
Revenue Breakdowns
Segment Analysis Beta
The financial segments are sourced from the SEC' 10-K statement.Revenue By Top Segments
Cingulate Inc. can't present it's sankey chart.
Historical Revenue By Segment
Last 3Y, in million USDCingulate Inc. can't present revenue by segment
Get PRO Today
With PRO you can bypass the blur for the segment revenues of Cingulate Inc..
If you want to see a demo, head over to the financial segments of AAPL